Cytochrome P-450 CYP3A Inhibitors

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A.

Also Known As:

CYP3A Inhibitors; CYP3A4 Inhibitors; CYP3A5 Inhibitors; CYP3A7 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors; P450 CYP3A Inhibitors; P450 CYP3A4 Inhibitors; P450 CYP3A5 Inhibitors; P450 CYP3A7 Inhibitors; CYP3A Inhibitor, P450; CYP3A4 Inhibitor, P450; CYP3A5 Inhibitor, P450; CYP3A5 Inhibitors, P450; CYP3A7 Inhibitor, P450; CYP3A7 Inhibitors, P450; Cytochrome P 450 CYP3A Inhibitor; Cytochrome P 450 CYP3A Inhibitors; Cytochrome P 450 CYP3A4 Inhibitor; Cytochrome P 450 CYP3A4 Inhibitors; Cytochrome P 450 CYP3A5 Inhibitor; Cytochrome P 450 CYP3A5 Inhibitors; Cytochrome P 450 CYP3A7 Inhibitor; Cytochrome P 450 CYP3A7 Inhibitors; Inhibitor, CYP3A; Inhibitor, CYP3A5; Inhibitor, CYP3A7; Inhibitor, Cyp3A4; Inhibitor, P450 CYP3A; Inhibitor, P450 CYP3A4; Inhibitor, P450 CYP3A5; Inhibitor, P450 CYP3A7; Inhibitors, CYP3A; Inhibitors, CYP3A4; Inhibitors, CYP3A5; Inhibitors, CYP3A7; Inhibitors, P450 CYP3A; Inhibitors, P450 CYP3A4; Inhibitors, P450 CYP3A7; CYP3A Inhibitor; CYP3A5 Inhibitor; CYP3A7 Inhibitor; Cyp3A4 Inhibitor; Cytochrome P-450 CYP3A Inhibitor; Cytochrome P-450 CYP3A4 Inhibitor; Cytochrome P-450 CYP3A5 Inhibitor; Cytochrome P-450 CYP3A7 Inhibitor; P450 CYP3A Inhibitor; P450 CYP3A4 Inhibitor; P450 CYP3A5 Inhibitor; P450 CYP3A7 Inhibitor

Networked: 142 relevant articles (3 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Cytochrome P-450 Enzyme Inhibitors: 8
        Cytochrome P-450 CYP3A Inhibitors: 142
  - Metabolic Side Effects of Drugs and Substances: 5
    - Cytochrome P-450 Enzyme Inhibitors: 8
      - Cytochrome P-450 CYP3A Inhibitors: 142

Experts

1.	Salem, Ahmed Hamed: 6 articles (02/2017 - 04/2014)
2.	Greenblatt, David J: 4 articles (08/2018 - 12/2008)
3.	Agarwal, Suresh K: 4 articles (02/2017 - 01/2016)
4.	Wong, Shekman L: 4 articles (02/2017 - 01/2016)
5.	Sharma, Sunil: 3 articles (01/2019 - 10/2014)
6.	Humerickhouse, Rod A: 3 articles (02/2017 - 01/2016)
7.	Mathijssen, Ron H J: 2 articles (01/2022 - 04/2018)
8.	Ratner, Lee: 2 articles (01/2022 - 01/2018)
9.	Makihara, Katsuya: 2 articles (07/2021 - 09/2017)
10.	Burhenne, Jürgen: 2 articles (01/2021 - 08/2006)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2022 - "Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)." 01/01/2023 - "Polypharmacy is common in patients undergoing treatment for hematological malignancies such as acute myeloid leukemia or chronic lymphocytic leukemia, and although venetoclax exposure has been well characterized with 1 concomitant CYP3A inhibitor, complex drug-drug interactions (DDIs) involving more than 1 inhibitor have not been systematically evaluated. " 10/12/2022 - "Gilteritinib, an FDA-approved tyrosine kinase inhibitor approved for the treatment of relapsed/refractory FLT3-mutated acute myeloid leukemia, is primarily eliminated via CYP3A4-mediated metabolism, a pathway that is sensitive to the co-administration of known CYP3A4 inhibitors, such as itraconazole. " 02/01/2017 - "The effect of posaconazole, a strong cytochrome P450 3A (CYP3A) inhibitor and commonly used antifungal agent, on the pharmacokinetic properties of venetoclax, a CYP3A substrate, was evaluated in patients with acute myeloid leukemia to determine the dose adjustments needed to manage this potential interaction. "
2.	Disease Progression 11/17/2022 - "A protease inhibitor called nirmatrelvir coupled with ritonavir (NMV/r), which acts as a CYP3A inhibitor, delivered as an oral formulation, has shown much promise in preventing disease progression in high-risk patients with no need for supplemental oxygen administration. "
3.	Ovarian Hyperstimulation Syndrome 11/01/2016 - "The efficacy of pathways inhibition and the combined effect of Everolimus (mTOR inhibitor) and Verapamil (CYP3A inhibitor) in ovarian hyperstimulation syndrome (OHSS) need to be tested. "
4.	Neoplasms (Cancer) 04/25/2023 - "Identification of CYP3A4 inhibitors as potential anti-cancer agents using pharmacoinformatics approach." 01/01/2023 - "These findings provide a high level of confidence that XHP significantly acts as a CYP3A4 inhibitor in anti-cancer therapeutic applications." 01/01/2022 - "Full doses of PCb chemotherapy are tolerable when given concurrently with ART in people living with human immunodeficiency virus with cancer, including patients receiving CYP3A4 inhibitors. " 01/01/2023 - "This study explored the pharmacokinetics, efficacy, and safety of zanubrutinib when coadministered with moderate or strong CYP3A inhibitors in 26 patients with relapsed or refractory B-cell malignancies. " 01/01/2023 - "A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies."
5.	Hemorrhage 01/01/2023 - "From the third quarter of 2010 to the first quarter of 2021, we retrieved 382 853 distinct cases of adverse events associated with DOACs, in which 1128 cases of bleeding were associated with coadministration of CYP3A4 inhibitors and DOACs. " 12/01/2021 - "Risk of serious bleeding increased in association with concurrent prescription of P-gp/CYP3A4 inhibitors. " 01/01/2022 - "Given the higher bleeding and mortality risks in NOAC-treated AF patients concomitantly using P-gp/CYP3A4 inhibitors, close monitoring is warranted." 10/03/2023 - "After multivariable adjustment, concomitant use of P-gp/CYP3A4 inhibitors was associated with significantly higher major bleeding (adjusted hazard ratio (aHR) 1.24, 95% confidence interval (CI) (1.18-1.30)) and all-cause mortality risks (aHR 1.07, 95%CI (1.02-1.11)), but not with thromboembolism in NOAC-treated AF patients. " 07/01/2023 - "Patients with AF receiving apixaban or rivaroxaban were included and followed-up until hospitalization for bleeding, death, discontinuation of apixaban or rivaroxaban, exposure to strong CYP3A4 inhibitor, or until December 31st 2019, whichever came first. "

Related Drugs and Biologics

1.	Itraconazole (Sporanox)
2.	Ritonavir (Norvir)
3.	Verapamil (Calan)
4.	Tyrosine Kinase Inhibitors
5.	Protease Inhibitors (Protease Inhibitor)
6.	Everolimus
7.	Oxygen (Dioxygen)
8.	nirmatrelvir
9.	gilteritinib
10.	Cytochrome P-450 CYP3A

Related Therapies and Procedures

1.	Contraindications
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)
4.	Polypharmacy
5.	Stents